A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It
This was a non-discretionary sale to cover tax withholding on vesting equity awards under a Rule 10b5-1 plan.
Overview
Michael Burkes Brophy, the chief financial officer of Natera, Inc. (NASDAQ:NTRA), sold 795 shares of common stock at $271.74 per share in transactions executed on August 3 and August 4, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($271.74); post-transaction value based on the August 4 market close ($275.19).
Details
Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the reproductive health and oncology diagnostics markets. The company's competitive advantage derives from its proprietary testing platforms and expanding clinical applications across multiple therapeutic areas. With a presence in Austin, Natera continues to scale its operations to capture growing demand for non-invasive and precision diagnostic solutions.
Source
Originally published at www.fool.com.